Newfield Therapeutics Corporation

Osterreichische Akademie Der Wissenschaften

Pba3 Biomed Gmbh

Karl Lohner

Dagmar Zweytick

Sabrina Riedl

Massimo Porro

Sylvie E Blondelle

Roman Jerala

Klaus Brandenburg

Andreja Majerle

Mateja Zorko

Bostjan Japelj

Jorg Andra

Ignacio Moriyon Uria

Jose Leiva Leon

Guillermo Martinez De Tejada De Garaizabal

Primoz Pristovsek

Gunter Deutsch

Guenter Deutsch

Joerg Andrae

The present invention relates to an isolated peptide for use in the treatment of cancer consisting of 12 to 50 amino acid residues comprising: at least two beta-strands, or at least two alpha-helices, or at least one beta-strand and at least one alpha-helix; wherein said beta-strands and/or alpha-helices are preferably separated from each other by at least one turn, wherein the peptide has a net positive charge of +7 or more; wherein said peptide comprises at least one peptide moiety having amino acid sequence (X)-X-(X)-X-(X)-X-(X)or the reverse sequence thereof, wherein Xis a hydrophobic amino acid, preferably selected from the group consisting of phenylalanine (Phe), alanine (Ala), leucine (Leu) and valine (Val), Xis a hydrophobic amino acid, preferably tryptophan (Trp), Xis selected from the group consisting of alanine (Ala), arginine (Arg), glutamine (Gln), asparagine (Asn), proline (Pro), isoleucine (Ile), leucine (Leu) and valine (Val), Xis selected from the group consisting of isoleucine (Ile), phenylalanine (Phe), tryptophan (Trp) and tyrosine (Tyr), Xis selected from the group consisting of arginine (Arg), lysine (Lys), tyrosine (Tyr) and phenylalanine (Phe), Xis a hydrophobic amino acid, preferably selected from the group consisting of isoleucine (Ile), tryptophan (Trp), valine (Val) and leucine (Leu), and Xis selected from the group consisting of arginine (Arg), lysine (Lys), isoleucine (Ile) and serine (Ser), and wherein M is 1 or 2, Q is 1 or 2, P is 2 or 3, and S is 1, 2, 3 or 4 under the proviso that if (X)is Arg-Arg S is 1; and wherein said peptide is devoid of intramolecular disulfide bonds.

Peptides for the treatment of cancer

The present invention relates to an isolated peptide for use in the treatment of cancer consisting of 12 to 50 amino acid residues comprising&#x2014;at least two beta-strands, or&#x2014;at least two alpha-helices or&#x2014;at least one beta-strand and at least one alpha-helix, &#x2014;wherein said beta-strands and/or alpha-helices are preferably separated from each other by at least one turn, wherein the peptide has a net positive charge of +7 or more; &#x2014;wherein said peptide comprises at least one peptide moiety having amino acid sequence (X)-X-(X)-X-(X)-X-(X)or the reverse sequence thereof, wherein Xis a hydrophobic amino acid, preferably selected from the group consisting of phenylalanine (Phe), alanine (Ala), leucine (Leu) and valine (Val), Xis a hydrophobic amino acid, preferably tryptophan (Trp), Xis selected from the group consisting of alanine (Ala), arginine (Arg), glutamine (Gin), asparagine (Asn), proline (Pro), isoleucine (lie), leucine (Leu) and valine (Val), Xis selected from the group consisting of isoleucine (Ile), phenylalanine (Phe), tryptophan (Trp) and tyrosine (Tyr), Xis selected from the group consisting of arginine (Arg), lysine (Lys), tyrosine (Tyr) and phenylalanine (Phe), Xis a hydrophobic amino acid, preferably selected from the group consisting of isoleucine (Ile), tryptophan (Trp), valine (Val) and leucine (Leu), and Xis selected from the group consisting of arginine (Arg), lysine (Lys), isoleucine (Ile) and serine (Ser), and wherein M is 1 or 2, Q is 1 or 2, P is 2 or 3, and S is 1, 2, 3 or 4 under the proviso that if (X)is Arg-Arg S is 1; and wherein said peptide is devoid of intramolecular disulfide bonds.

The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.

Antimicrobial peptides

Growing community of inventors

Graz, Austria

Karl Lohner